Liminal BioSciences (LMNL) 6-K 8 Aug 23 2023 Q2 Liminal BioSciences Reports Second Quarter Financial Results 2023 Financial data

Cover Page

Cover Page	6 Months Ended
	Jun. 30, 2023
Document Information [Line Items]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Registrant Name	LIMINAL BIOSCIENCES INC.
Entity Central Index Key	0001351172
Current Fiscal Year End Date	--12-31

Consolidated Statements of Fina

Consolidated Statements of Financial Position (Unaudited) - CAD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 19,312	$ 37,144
Accounts receivable	788	1,177
Prepaids	1,602	2,997
Assets held for sale (note 3)	3,937	0
Total current assets	25,639	41,318
Other long-term assets	357	243
Capital assets	327	4,344
Right-of-use assets	895	1,146
Intangible assets (note 4)	4,412	3,240
Deferred tax assets	168	168
Total assets	31,798	50,459
Current liabilities
Accounts payable and accrued liabilities	5,394	5,968
Current portion of lease liabilities (note 5)	679	735
Current portion of provision (note 6)	3,166	3,400
Total current liabilities	9,239	10,103
Long-term portion of lease liabilities (note 5)	528	752
Long-term portion of provision (note 6)	0	3,290
Warrant liability (note 7)	556	106
Total liabilities	10,323	14,251
EQUITY
Share capital (note 9a)	981,162	979,849
Contributed surplus (note 9b)	46,503	45,973
Warrants (note 9c)	95,856	95,856
Accumulated other comprehensive loss	(3,172)	(3,169)
Deficit	(1,098,874)	(1,082,301)
Total equity	21,475	36,208
Total liabilities and equity	$ 31,798	$ 50,459

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - CAD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Profit or loss [abstract]
Revenues	$ 112	$ 157	$ 248	$ 157
Expenses
Research and development expenses	4,339	3,942	8,508	8,317
Administration expenses	4,776	4,505	8,335	9,205
Gain on foreign exchange	(65)	(1,745)	(76)	(959)
Finance costs	(175)	867	(413)	2,225
Loss on extinguishment of liabilities (note 8)	0	0	0	212
Change in fair value of financial instruments measured at fair value through profit or loss (note 7)	212	(1,064)	450	(1,307)
Loss from continuing operations, net of taxes of $nil	(8,975)	(6,348)	(16,556)	(17,536)
Discontinued operations
Loss on sale of discontinued operations, net of income taxes $nil (note 3)	(98)	0	(98)	(600)
Income (loss) from discontinued operations, net of taxes of $nil (note 3)	(68)	123	81	747
Total income (loss) from discontinued operations	(166)	123	(17)	147
Net loss	(9,141)	(6,225)	(16,573)	(17,389)
Net (loss) income attributable to:
Non-controlling interests in continuing operations	0	291	0	(168)
Owners of the parent
- Continuing operations	(8,975)	(6,639)	(16,556)	(17,368)
- Discontinued operations	(166)	123	(17)	147
Total Net loss attributable to owners of the parent from continuing and discontinued operations	(9,141)	(6,516)	(16,573)	(17,221)
Net loss	$ (9,141)	$ (6,225)	$ (16,573)	$ (17,389)
Income (Loss) per share attributable to the owners of the parent basic and diluted:
From continuing operations, basic	$ (2.89)	$ (2.14)	$ (5.33)	$ (5.6)
From continuing operations, diluted	(2.89)	(2.14)	(5.33)	(5.6)
From discontinued operations, basic	(0.05)	0.04	(0.01)	0.05
From discontinued operations, diluted	(0.05)	0.04	(0.01)	0.05
Total loss per share, basic	(2.94)	(2.1)	(5.34)	(5.55)
Total loss per share, diluted	$ (2.94)	$ (2.1)	$ (5.34)	$ (5.55)
Weighted average number of outstanding shares (in thousands)	3,104	3,104	3,104	3,104

Consolidated Statements of Op_2

Consolidated Statements of Operations (Unaudited) (Parenthetical) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Profit or loss [abstract]
Loss from continuing operations, net of taxes	$ 0	$ 0	$ 0	$ 0
Gain (loss) on sale of discontinued operations, net of income taxes	0	0	0	0
Income (loss) from discontinued operations, net of taxes	$ 0	$ 0	$ 0	$ 0

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement of comprehensive income [abstract]
Net loss	$ (9,141)	$ (6,225)	$ (16,573)	$ (17,389)
Items that may be subsequently reclassified to profit and loss:
Exchange differences on translation of foreign operations from continuing operations	(2)	(7)	(3)	4
Total other comprehensive income (loss)	(2)	(7)	(3)	4
Total comprehensive loss	(9,143)	(6,232)	(16,576)	(17,385)
Total comprehensive income (loss) attributable to:
Non-controlling interests	0	291	0	(168)
Owners of the parent- Continuing operations	(8,977)	(6,646)	(16,559)	(17,364)
Owners of the parent- Discontinued operations	(166)	123	(17)	147
Total comprehensive loss	$ (9,143)	$ (6,232)	$ (16,576)	$ (17,385)

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity (Unaudited) - CAD ($) $ in Thousands	Total	Share Capital	Contributed Surplus	Warrants	Foreign Currency Translation Reserve	Deficit	Total Equity (Deficiency) Attributable to Owners of the Parent	Non-controlling Interests
Beginning balance at Dec. 31, 2021	$ 33,881	$ 979,849	$ 44,109	$ 95,856	$ (3,010)	$ (1,074,167)	$ 42,637	$ (8,756)
Net loss	(17,389)					(17,221)	(17,221)	(168)
Foreign currency translation reserve	4				4		4
Share-based payments expense	1,156		1,156				1,156
Ending balance at Jun. 30, 2022	17,652	979,849	45,265	95,856	(3,006)	(1,091,388)	26,576	(8,924)
Beginning balance at Dec. 31, 2022	36,208	979,849	45,973	95,856	(3,169)	(1,082,301)	36,208	0
Net loss	(16,573)					(16,573)	(16,573)
Foreign currency translation reserve	(3)				(3)		(3)
Issuance of shares (note 9a)	1,313	1,313					1,313
Share-based payments expense	530		530				530
Ending balance at Jun. 30, 2023	$ 21,475	$ 981,162	$ 46,503	$ 95,856	$ (3,172)	$ (1,098,874)	$ 21,475	$ 0

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Cash flows used in operating activities
Net loss from continuing operations during the period	$ (8,975)	$ (6,348)	$ (16,556)	$ (17,536)
Net income (loss) from discontinued operations during the year	(166)	123	(17)	147
Adjustments to reconcile net loss to cash flows used in operating activities:
Finance costs and foreign exchange			(521)	855
Loss on sale of discontinued operations			98	600
Change in fair value of financial instruments measured at fair value through profit or loss			450	(1,307)
Loss on extinguishment of liabilities	0	0	0	212
Provision expense			(346)	(1,028)
Payment of principal elements of provision			(3,238)	0
Share-based payments expense			530	1,156
Depreciation of capital assets			78	170
Depreciation of right-of-use assets			263	252
Amortization of intangible assets			142	141
Cash flows from (used in) operations before changes in working capital			(19,117)	(16,338)
Change in non-cash working capital items			996	2,515
Cash flows used in operating activities			(18,121)	(13,823)
Cash flows used in financing activities
Repayment of principal on long-term debt			0	(39,123)
Payments of principal on lease liabilities			(304)	(294)
Payment of interest on lease liabilities			(102)	(98)
Debt, share and warrants issuance and repayment costs			0	(40)
Cash flows used in financing activities			(406)	(39,555)
Cash flows from investing activities
Additions to capital assets			0	(13)
Additions to intangible assets			0	(3)
Interest received			677	142
Cash flows used in investing activities			677	126
Net change in cash and cash equivalent during the period			(17,850)	(53,252)
Net effect of currency exchange rate on cash and cash equivalents			18	567
Cash, beginning of period			37,144	108,490
Cash and cash equivalents, end of the period	19,312	55,805	19,312	55,805
Comprising of:
Cash	19,311	42,914	19,311	42,914
Cash equivalents	1	12,891	1	12,891
Total cash and cash equivalents	$ 19,312	$ 55,805	$ 19,312	$ 55,805

Nature of operations and going

Nature of operations and going concern	6 Months Ended
	Jun. 30, 2023
Disclosure Of Nature Of Operations And Going Concern [Abstract]
Nature of operations and going concern	1. N ature of operations and going concern Liminal BioSciences Inc., or Liminal or the Company, is incorporated under the Canada Business Corporations Act and is a publicly traded development stage biopharmaceutical company (Nasdaq symbol: LMNL) focused on discovering and developing distinctive novel small molecule therapeutics that modulate G protein-coupled receptors, or GPCR, pathways with the intent of developing best/first-in-class therapeutics for the treatment of metabolic, for inflammatory and fibrotic diseases with significant unmet needs, using its integrated drug discovery platform, medicinal chemistry expertise and deep understanding of the GPCR biology. The Company’s pipeline is currently made up of three development programs. The candidate selected for clinical development, LMNL6511, a selective antagonist for the GPR84 receptor, is expected to commence a Phase 1 clinical trial in the second half of 2023. The Company is also developing potential OXER1 antagonists and GPR40 agonists, both of which are at the preclinical stage. On February 1, 2023, the Company performed a share consolidation of all its issued and outstanding common shares, stock options and warrants on the basis of a consolidation ratio of ten pre-consolidation shares to one post consolidation share. The quantities and per unit prices of the Company's common shares, stock options and warrants presented in these interim condensed consolidated financial statements have been retroactively adjusted to give effect to the share consolidation. The Company’s registered office is located at 231 Dundas Street East, Belleville, Ontario, K8N 1E2 and its principal executive office is located at 440, Boul. Armand-Frappier, suite 300, Laval, Québec, Canada, H7V 4B4. Liminal has active business operations in Canada and the United Kingdom. Structured Alpha LP, or SALP, is Liminal’s majority and controlling shareholder and is considered Liminal’s parent entity for accounting purposes. Thomvest Asset Management Ltd., or Thomvest, is the general partner of SALP and the ultimate controlling parent, for accounting purposes, of Liminal is The 2003 TIL Settlement. The interim condensed consolidated financial statements for the quarter and six months ended June 30, 2023, or interim financial statements, are presented in Canadian dollars, $ or CAD, and have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, on a going concern basis, which presumes the Company will continue its operations for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business. During the six months ended June 30, 2023, the Company incurred a net loss from continuing operations of $ 16.6 million ($ 17.5 million for the six months ended June 30, 2022) and had negative operating cash flows, including continuing and discontinued operations, of $ 18.1 million ($ 13.8 million for the six months ended June 30, 2022). At June 30, 2023, the Company had an accumulated deficit of $ 1,098.9 million ($ 1,082.3 million at December 31, 2022) and a working capital of $ 16.4 million ($ 31.2 million at December 31, 2022). The Company’s cash runway is dependent on the research programs currently underway, the pace of their progression and their outcome, as well as those planned to be undertaken in the short term. As such, there is always a degree of uncertainty in regard to the outcome or cost of those programs. The cash runway is also dependent on decisions the Company makes in terms of managing its capital, including raising capital through the issuance of debt or equity, and the Company's ability to conclude such financing transactions at an acceptable cost. The need to complete financing transactions in the future is likely to continue until the Company can generate sufficient product revenues to finance its cash requirements. Management may revert to a variety of sources for financing future cash needs including public or private equity offerings, debt financings, strategic collaborations, alliances and licensing arrangements, grant funding, selling non-core assets or other sources. Despite the Company’s efforts to obtain the necessary funding and improve profitability of its operations, there can be no assurance of its success in doing so, especially with respect to its access to further funding on acceptable terms, if at all. The Company currently expects that its existing resources will be sufficient to fund its planned operations and expenditures until December 2023. These circumstances indicate the existence of a material uncertainty that may cast substantial doubt about the Company’s ability to continue as a going concern. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s preclinical, clinical and regulatory efforts, which are critical to the realization of its business plan. These interim financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

Material accounting policies

Material accounting policies	6 Months Ended
	Jun. 30, 2023
Significant Accounting Policies [Abstract]
Material accounting policies	2. Material accounting policies a) Accounting framework These interim financial statements have been prepared in accordance with IAS 34, Interim financial reporting . Accordingly, certain information and footnote disclosure normally included in annual financial statements prepared in accordance with IFRS, have been omitted or condensed. These interim financial statements should therefore be read in conjunction with the audited annual consolidated financial statements for the year ended December 31, 2022, which have been prepared in accordance with IFRS and can be found at www.sec.gov/edgar and at www.sedar.com. These interim financial statements were approved for issue on August 8, 2023 by the Company’s Audit, Risk and Finance committee as delegated by the Board of Directors. b) New standards and interpretations adopted The accounting policies used in our interim financial statements are consistent with those we applied in our December 31, 2022 audited annual consolidated financial statements except for the adoption of the following amendments on January 1, 2023. Amendments to I AS 8, Accounting policies , Changes in Accounting Estimates and Errors (IAS 8) - The amendments to IAS 8 introduce a definition of accounting estimates and provide clarifications to distinguish accounting policies from accounting estimates. The amendments are applicable retrospectively and are effective for annual reporting periods beginning on or after January 1, 2023 with earlier application permitted. c) New standards and interpretations not yet adopted The IFRS accounting standards, amendments, and interpretations that the Company reasonably expects may have a material impact on the disclosures, the financial position or results of operations of the Company when applied at a future date are as follows: Amendments IAS 1, Presentation of Financial Statements (IAS 1) - IAS 1 has been revised to clarify how to classify debt and other liabilities as current or non-current. The amendments help to determine whether, in the statement of financial position, debt and other liabilities with an uncertain settlement date should be classified as current (due or potentially due to be settled within one year) or non-current. The amendments also include clarifying the classification requirements for debt an entity might settle by converting it into equity. The amendments are applicable retrospectively and are effective for annual reporting periods beginning on or after January 1, 2024 with earlier application permitted. The Company concluded that these amendments will not have an impact on its financial statements at the date of adoption and for the comparative periods. d) Significant accounting judgements and estimation uncertainty The preparation of these interim financial statements requires the use of judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the accompanying disclosures. The uncertainty that is often inherent in estimates and assumptions could result in material adjustments to assets or liabilities affected in future periods. The significant judgments made and critical accounting estimates applied by us and disclosed in the consolidated financial statements for the year ended December 31, 2022, remain unchanged.

Discontinued operations

Discontinued operations	6 Months Ended
	Jun. 30, 2023
Discontinued Operations [Abstract]
Discontinued operations	3. Discontinued operations Discontinued operations for the periods presented in the interim financial statements comprise the revenues and expenses of operations and the gains and transaction expenses related thereto, for the following activities, assets and liabilities: • the obligations towards a Contract Development Manufacturing Organization, or CDMO, it retained upon the sale of the plasma derived business; • the operating costs of the previously owned Labrosse facility, located in Pointe-Claire, Québec; and • the operating costs of the Company's dormant manufacturing facility located in Belleville, Ontario, or the Belleville facility. All amounts relating to the activities above have been presented as discontinued operations in the current and prior periods. More specifically, we have restated the prior periods to remove the impact of those operations from all lines in the financial statements (revenues, cost of sales and production cost, R&D and administration, selling and marketing being the lines most impacted) and have reclassified those results to the income (loss) from discontinued operations lines in the interim financial statements. During the six months ended June 30, 2023, the Belleville facility, formerly part of the plasma-derived therapeutics segment and previously classified as property, plant and equipment, met the criteria to be classified as held for sale, and is presented as such in the consolidated statement of financial position at June 30, 2023. Gain on sale of discontinued operations During the six months ended June 30, 2023 and 2022, the Company recorded an indemnification adjustment expense of $ 98 and $ 600 , respectively, which represents a disputed research and development tax credit claim and interest with a taxation authority. Results and cash flows from discontinued operations The net loss from discontinued operations for the quarters and six months ended June 30, 2023 and 2022 are presented below: Quarter ended June30, Six months ended June 30, 2023 2022 2023 2022 Revenues $ — $ 8 $ — $ 15 Expenses Research and development expenses 1) ( 14 ) ( 389 ) ( 345 ) ( 1,201 ) Administration expenses 80 142 261 336 Gain on foreign exchange — ( 12 ) — ( 12 ) Finance costs 2 144 3 145 Income (loss) from discontinued $ ( 68 ) $ 123 $ 81 $ 747 1) Expense (income) recognized in regards to an agreement with a CDMO which in the comparative period is accounted for in part as a lease (note 5) and an onerous contract (note 6). These expenses (income) are due to changes to the discounted value caused by changes in inflation and discount rates. The consolidated statements of cash flows for the six months ended June 30, 2023 and 2022 were not restated to present the cash flows from the discontinued operations separately as the Company selected to provide this information in the present note. The cash flows from the discontinued operations and the gain on sale of discontinued operations for the six months ended June 30, 2023 and 2022 are presented in the following table: June 30, June 30, Cash flows used in operating activities $ ( 264 ) $ ( 323 ) Cash flows utilized during the period $ ( 264 ) $ ( 323 )

Intangible assets

Intangible assets	6 Months Ended
	Jun. 30, 2023
Disclosure of detailed information about intangible assets [abstract]
Intangible assets	4. Intangible assets Licenses and Patents Software Total Cost Balance at January 1, 2023 $ 145,759 $ 5,477 $ 265 $ 151,501 Additions 1,312 — — 1,312 Disposals — ( 420 ) — ( 420 ) Effect of foreign exchange differences — ( 16 ) 1 ( 15 ) Balance at June 30, 2023 $ 147,071 $ 5,041 $ 266 $ 152,378 Accumulated amortization Balance at January 1, 2023 $ 142,562 $ 5,439 $ 260 $ 148,261 Amortization expense 121 21 — 142 Disposals — ( 420 ) — ( 420 ) Effect of foreign exchange differences — ( 16 ) ( 1 ) ( 17 ) Balance at June 30, 2023 $ 142,683 $ 5,024 $ 259 $ 147,966 Carrying amounts At June 30, 2023 $ 4,388 $ 17 $ 7 $ 4,412 At December 31, 2022 3,197 38 5 3,240 During the quarter ended June 30, 2023, the nomination of LMNL6326 as the lead preclinical candidate for the OXER1 program triggered a milestone event pursuant to the share purchase agreement, or SPA, dated July 17, 2020 , entered into between the Company and the selling shareholders where the Company acquired 100 % of the issued and outstanding common shares of Fairhaven Pharmaceuticals Inc., or Fairhaven, a company with a preclinical research program of small molecule antagonists. As a result of the achievement of this milestone, the Company paid an additional amount of $ 1,312 to the selling shareholders, by issuing 145,312 common shares of the Company equal to the amount of the milestone payment divided by the five -trading day volume weighted average trading price of the Company's common shares on Nasdaq immediately preceding the milestone payment date (note 9a).

Lease liabilities

Lease liabilities	6 Months Ended
	Jun. 30, 2023
Lease liabilities [abstract]
Lease liabilities	5. Lease liabilities The transactions affecting the lease liabilities during the six months ended June 30, 2023 were as follows: Balance at January 1, 2023 $ 1,487 Additions 12 Interest expense 109 Payments ( 406 ) Lease modification and other remeasurements — Effect of foreign exchange differences 5 Balance at June 30, 2023 $ 1,207 Less current portion of lease liabilities ( 679 ) Long-term portion of lease liabilities $ 528

Provisions

Provisions	6 Months Ended
	Jun. 30, 2023
Restructuring provision [abstract]
Provisions	6. Provisions The transactions affecting the provisions during the six months ended June 30, 2023 were as follows: Balance at January 1, 2023 $ 6,690 Decrease to provision during the period ( 320 ) Payments ( 3,238 ) Interest expense 60 Effect of changes in the discount rate ( 26 ) Balance at June 30, 2023 $ 3,166 Less current portion of provision ( 3,166 ) Long-term portion of provision $ —

Warrant liability

Warrant liability	6 Months Ended
	Jun. 30, 2023
Warrant Liability [Abstract]
Warrant Liability	7. Warrant liability On February 1, 2023, the Company performed a ten-to-one share consolidation of its common shares, stock options and warrants. The quantities and per unit prices presented throughout the consolidated financial statements, including this note, have been retroactively adjusted to give effect to the share consolidation. As part of the consideration for the private placement completed on November 3, 2020 where SALP and another investor participated equally, and a subsequent amendment to this private placement agreement made on November 25, 2020, the Company issued a total of 789,472 warrants that expire on November 3, 2025 . Both of these issuances combined are referred to as the November 2020 warrants. Each warrant can be exercised to acquire one common share at an exercise price initially set at USD 55.0 and that can be reduced if equity financings are completed at a lower price before its expiry. The November 2020 warrants do not meet the definition of an equity instrument since the exercise price is denominated in USD which is different than the functional currency of Liminal which is the CAD. Consequently, they are accounted for as a financial instrument, presented as a warrant liability in the consolidated statement of financial position and carried at fair value through profit or loss. The fair value of the November 2020 warrants was $ 556 and $ 106 at June 30, 2023 and December 31, 2022, respectively. The fair value for the November 2020 warrants held by SALP was $ 278 and $ 53 on those same dates. A loss of $ 212 and $ 450 , resulting from the change in fair value of the November 2020 warrants during the quarter and the six months ended June 30, 2023, respectively (a gain of $ 1,064 and $ 1,307 for the quarter and six months ended June 30, 2022, respectively), was recognized in the consolidated statement of operations. The fair value of the November 2020 warrants on the various dates discussed above was calculated using a Black-Scholes option pricing model in a Monte Carlo simulation in order to evaluate the downward adjustment mechanism to the exercise price. The assumptions used at the different valuation dates are provided in the table below: June 30, December 31, 2023 2022 Underlying common share fair value (in USD) $ 6.28 $ 3.25 Remaining life until expiry 2.3 2.8 Volatility 71.0 % 51.0 % Risk-free interest rate 4.75 % 4.26 % Expected dividend rate — — Fair value of a warrant calculated using a $ 0.19 $ — Fair value of exercise price adjustment mechanism $ 0.53 $ 0.12 Illiquidity discount 26.0 % 20.0 % Fair value of a warrant (in USD) $ 0.53 $ 0.10 Fair value of a warrant (in CAD) $ 0.70 $ 0.13

Long-term debt

Long-term debt	6 Months Ended
	Jun. 30, 2023
Disclosure of detailed information about borrowings [abstract]
Long-term debt	8. Long-term debt On February 15, 2022, the Company settled the entirety of the first and second term loans, representing an aggregate principal amount of $ 39,123 and the stated interest accrued of $ 484 , for an amount of $ 39,123 , thus terminating the consolidated loan agreement with SALP and releasing the security interests granted by the Company over its assets pursuant to the loan agreement and related documents. The difference between the carrying amount of the loans extinguished and the cash payment of $ 292 was recorded as a loss on extinguishment of liabilities. The Company incurred $ 40 in legal fees in relation to the prepayment, which were recorded against the loss on extinguishment of liabilities. The repayment also terminated the royalty stream agreement with SALP resulting in the derecognition of the royalty payment obligation to SALP included in other long-term liabilities and the recognition of a gain on extinguishment of liabilities of $ 120 . In concurrence with the repayment, the 16,873 warrants held by SALP and having an exercise price of $ 152.10 per common share (note 9c) were cancelled.

Share capital and other equity

Share capital and other equity instruments	6 Months Ended
	Jun. 30, 2023
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Share capital and other equity instruments	9. Share capital and other equity instruments a) Share capital On February 1, 2023, the Company performed a share consolidation of all its issued and outstanding common shares, stock options and warrants on the basis of a consolidation ratio of ten pre-consolidation shares to one post-consolidation share. The quantities and per unit prices of the Company's common shares, stock options and warrants presented in these interim financial statements have been retroactively adjusted to give effect to the share consolidation. Authorized and without par value Common shares: unlimited number authorized, participating, carrying one vote per share, entitled to dividends. Preferred shares: unlimited number authorized, issuable in one or more series. - Series A preferred shares: unlimited number authorized, no par value, non-voting, ranking in priority to the common shares, entitled to the same dividends as the common shares, non-transferable, redeemable at the redemption amount offered for the common shares upon a change in control event. No preferred shares have been issued. At June 30, 2023 and 2022, the number of common shares outstanding were as follows: June 30, 2023 June 30, 2022 Number Amount Number Amount Balance - beginning of period 3,104,222 $ 979,849 3,104,222 $ 979,849 Shares issued for milestone achievement (note 4) 145,312 1,313 — — Balance - end of period 3,249,534 $ 981,162 3,104,222 $ 979,849 b) Contributed surplus (Share-based payments) Stock options For stock options having a CAD exercise price, the changes in the number of stock options outstanding during the six months ended June 30, 2023 and 2022 were as follows: June 30, 2023 June 30, 2022 Weighted Weighted average average exercise price exercise price Number ($) Number ($) Balance - beginning of period 101,629 $ 214.46 102,805 $ 215.29 Forfeited ( 1,709 ) 146.12 — — Expired — — ( 8 ) 21,225.00 Balance - end of period 99,920 $ 215.63 102,797 $ 213.65 For options having a USD exercise price, the changes in the number of stock options outstanding during the quarters ended June 2023, and 2022 were as follows: June 30, 2023 June 30, 2022 Weighted Weighted average average exercise price exercise price Number (USD) Number (USD) Balance - beginning of period 130,916 $ 21.52 74,900 $ 34.88 Granted 44,600 3.99 60,850 6.70 Forfeited ( 5,166 ) 16.34 ( 4,500 ) 18.08 Balance - end of period 170,350 $ 17.09 131,250 $ 22.39 2023 In March 2023, there were two option grants issued of which 41,500 stock options having an exercise price of USD 3.99 and vesting over a period of up to four years were issued to executives and 3,100 stock options having an exercise price of USD 3.99 and vesting over a period of up to four years were issued to employees. 2022 In March 2022, there were two option grants issued of which 11,500 stock options, having an exercise price of USD 10.20 and vesting over a period of up to four years were issued to executives and 5,000 stock options, having an exercise price of USD 10.20 and vesting over a period of up to four years were issued to a member of the Board of Directors. The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options at the date of grant. The weighted average inputs into the model and the resulting grant date fair values during the quarters ended June 30, 2023 and 2022 were as follows: June 30, June 30, 2023 2022 Expected dividend rate — — Expected volatility of share price 117.2 % 115.8 % Risk-free interest rate 3.54 % 2.85 % Expected life in years 6.8 6.8 Weighted average grant date fair value $ 4.65 $ 7.50 At June 30, 2023, stock options issued and outstanding denominated in CAD and USD by range of exercise price are as follows: Weighted Weighted Weighted Range of exercise remaining average average price for stock option Number contractual life exercise price Number exercise price issued in CAD outstanding (in years) ($) exercisable ($) $ 119.90 -$ 146.35 15,399 6.8 $ 136.57 13,079 $ 136.15 $ 146.36 -$ 211.05 78,973 5.9 152.10 68,197 152.10 $ 211.06 - $ 2,130.00 5,025 5.9 358.66 5,025 358.66 $ 2,130.01 -$ 20,700.00 523 5.0 10,761.57 523 10,761.57 99,920 6.1 $ 215.63 86,824 $ 225.56 Weighted Weighted Weighted Range of exercise remaining average average price for stock option Number contractual life exercise price Number exercise price issued in USD outstanding (in years) (USD) exercisable (USD) $ 3.99 -$ 4.75 54,600 9.7 $ 4.01 — $ — $ 4.76 -$ 7.80 37,850 8.9 5.40 14,370 5.40 $ 7.81 - $ 15.95 16,500 8.7 10.20 5,169 10.20 $ 15.96 -$ 41.80 31,400 8.2 27.56 18,939 31.42 $ 41.81 - $ 108.00 30,000 7.4 48.48 27,164 48.28 170,350 8.7 $ 17.09 65,642 $ 31.03 A share-based payment compensation expense of $ 243 and $ 530 was recorded for the stock options for the quarter and six months ended June 30, 2023, respectively ($ 537 and $ 1,156 for the quarter and six months ended June 30, 2022, respectively). Share-based payments expense The total share-based payments compensation expense has been included in the consolidated statements of operations for the quarters and six months ended June 30, 2023 and 2022 as indicated in the following table: Quarter ended June 30, Six months ended June 30, 2023 2022 2023 2022 Research and development expenses $ 98 $ 256 $ 231 $ 523 Administration expenses 145 281 299 633 $ 243 $ 537 $ 530 $ 1,156 c) Warrants The following table presents the number of warrants outstanding with an exercise price in CAD during the six months ended June 30, 2023 and 2022: June 30, 2023 June 30, 2022 Weighted Weighted average average exercise price exercise price Number ($) Number ($) Balance of warrants - beginning of period 400 $ 30,000.00 17,273 $ 843.30 Cancelled (note 8) — — ( 16,873 ) 152.10 Expired ( 400 ) 30,000.00 — — Balance of warrants - end of period — $ — 400 $ 30,000.00 There were no changes in the number of warrants having a USD exercise price during the quarter ended June 30, 2023 and 2022. These are the same warrants presented as a warrant liability (note 7) and they are listed here with the warrants classified as equity instruments, simply so the readers may see all the warrants outstanding together. At June 30, 2023, the number of warrants outstanding by exercise price were as follows: June 30, 2023 Weighted average exercise price Number (USD) Balance of warrants - end of period 789,472 $ 55.00 The 789,472 warrants shown in the table above, are those accounted for as a warrant liability (note 7) and are included in this note in order to present all the outstanding warrants in aggregate in the tables above. The warrants outstanding at June 30, 2023, their exercise price in USD, expiry rate and the overall weighted average exercise price in both currencies are as follows: Number Expiry Exercise Warrants outstanding with an exercise price in USD 789,472 November 2025 $ 55.00 On February 15, 2022, the 16,873 warrants having an exercise price of $ 152.10 were cancelled (note 8).

Related party transactions

Related party transactions	6 Months Ended
	Jun. 30, 2023
Related party transactions [abstract]
Related party transactions	10. Related party transactions Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note. Details of transactions between the Company and other related parties are disclosed below and in other notes according to the nature of the transactions. These transactions have been recorded at the exchange amount, meaning the amount agreed to between the parties. At June 30, 2023, a former CEO had a balance of $ 197 ($ 197 at December 31, 2022), owing to the Company under a tax equalization program. The amount is required to be repaid to the Company following the receipt of a refund by the former employee from the taxation authority for each of the two years covered by the program. At December 31, 2022, the Company received the reimbursment of the first year. The remaining amount is expected to be received once the tax return of the second and final year of the program has been assessed by the appropriate government agencies. All material transactions with SALP are disclosed in notes 7, 8 and 11 where the particular transactions are disclosed, and otherwise in this note. During the quarter and six months ended June 30, 2023, the Company also recorded legal expenses of $ 53 and $ 117 , respectively ($ 46 and $ 205 for the quarter and six months ended June 30, 2022), incurred by SALP, that is required to be reimbursed pursuant to the subscription agreement signed with SALP on April 14, 2019. In connection with the milestone event that resulted from the nomination of LMNL6326 as the lead preclinical candidate for the OXER1 program, a cash payment of $ 188 was made to a Board member, who is also a consultant to the Company.

Subsequent event

Subsequent event	6 Months Ended
	Jun. 30, 2023
Disclosure of non-adjusting events after reporting period [abstract]
Subsequent event	11. Subsequent event On July 11, 2023, the Company entered into a Definitive Arrangement Agreement (the "Agreement") with SALP. Under the terms of the Arrangement Agreement, Liminal BioSciences shareholders (other than SALP and its affiliates or associates) will receive USD 8.50 in cash per Common Share, which represents a premium of approximately 135 % over Liminal BioSciences' closing share price on the Nasdaq Capital Market ("Nasdaq") on April 4, 2023, which was the last full trading day prior to the public announcement of SALP's initial non-binding proposal to acquire the remaining Common Shares of Liminal BioSciences that it does not already own, and is $ 1.00 per Common Share more than SALP's initial non-binding proposal.The transaction is expected to be completed pursuant to a court-approved plan of arrangement under section 192 of the Canada Business Corporations Act and is subject to the satisfaction of customary closing conditions, including (without limitation) court approval and the approval of the shareholders of Liminal BioSciences. After completion of the transaction, Liminal BioSciences expects to no longer be subject to the reporting requirements of applicable Canadian securities legislation or the U.S. Securities Exchange Act of 1934, as amended, and its common shares will be delisted from Nasdaq.

Material accounting policies (P

Material accounting policies (Policies)	6 Months Ended
	Jun. 30, 2023
Significant Accounting Policies [Abstract]
Accounting framework	a) Accounting framework These interim financial statements have been prepared in accordance with IAS 34, Interim financial reporting . Accordingly, certain information and footnote disclosure normally included in annual financial statements prepared in accordance with IFRS, have been omitted or condensed. These interim financial statements should therefore be read in conjunction with the audited annual consolidated financial statements for the year ended December 31, 2022, which have been prepared in accordance with IFRS and can be found at www.sec.gov/edgar and at www.sedar.com. These interim financial statements were approved for issue on August 8, 2023 by the Company’s Audit, Risk and Finance committee as delegated by the Board of Directors.
New standards and interpretations adopted	b) New standards and interpretations adopted The accounting policies used in our interim financial statements are consistent with those we applied in our December 31, 2022 audited annual consolidated financial statements except for the adoption of the following amendments on January 1, 2023. Amendments to I AS 8, Accounting policies , Changes in Accounting Estimates and Errors (IAS 8) - The amendments to IAS 8 introduce a definition of accounting estimates and provide clarifications to distinguish accounting policies from accounting estimates. The amendments are applicable retrospectively and are effective for annual reporting periods beginning on or after January 1, 2023 with earlier application permitted.
New Standards and interpretations not yet adopted	c) New standards and interpretations not yet adopted The IFRS accounting standards, amendments, and interpretations that the Company reasonably expects may have a material impact on the disclosures, the financial position or results of operations of the Company when applied at a future date are as follows: Amendments IAS 1, Presentation of Financial Statements (IAS 1) - IAS 1 has been revised to clarify how to classify debt and other liabilities as current or non-current. The amendments help to determine whether, in the statement of financial position, debt and other liabilities with an uncertain settlement date should be classified as current (due or potentially due to be settled within one year) or non-current. The amendments also include clarifying the classification requirements for debt an entity might settle by converting it into equity. The amendments are applicable retrospectively and are effective for annual reporting periods beginning on or after January 1, 2024 with earlier application permitted. The Company concluded that these amendments will not have an impact on its financial statements at the date of adoption and for the comparative periods.
Significant accounting judgements and estimation uncertainty	d) Significant accounting judgements and estimation uncertainty The preparation of these interim financial statements requires the use of judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the accompanying disclosures. The uncertainty that is often inherent in estimates and assumptions could result in material adjustments to assets or liabilities affected in future periods. The significant judgments made and critical accounting estimates applied by us and disclosed in the consolidated financial statements for the year ended December 31, 2022, remain unchanged.

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2023
Discontinued Operations [Abstract]
Summary of Results and Cash Flows from Discontinued Operations	The net loss from discontinued operations for the quarters and six months ended June 30, 2023 and 2022 are presented below: Quarter ended June30, Six months ended June 30, 2023 2022 2023 2022 Revenues $ — $ 8 $ — $ 15 Expenses Research and development expenses 1) ( 14 ) ( 389 ) ( 345 ) ( 1,201 ) Administration expenses 80 142 261 336 Gain on foreign exchange — ( 12 ) — ( 12 ) Finance costs 2 144 3 145 Income (loss) from discontinued $ ( 68 ) $ 123 $ 81 $ 747 1) Expense (income) recognized in regards to an agreement with a CDMO which in the comparative period is accounted for in part as a lease (note 5) and an onerous contract (note 6). These expenses (income) are due to changes to the discounted value caused by changes in inflation and discount rates. The cash flows from the discontinued operations and the gain on sale of discontinued operations for the six months ended June 30, 2023 and 2022 are presented in the following table: June 30, June 30, Cash flows used in operating activities $ ( 264 ) $ ( 323 ) Cash flows utilized during the period $ ( 264 ) $ ( 323 )

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2023
Disclosure of detailed information about intangible assets [abstract]
Summary of Intangible Assets	Licenses and Patents Software Total Cost Balance at January 1, 2023 $ 145,759 $ 5,477 $ 265 $ 151,501 Additions 1,312 — — 1,312 Disposals — ( 420 ) — ( 420 ) Effect of foreign exchange differences — ( 16 ) 1 ( 15 ) Balance at June 30, 2023 $ 147,071 $ 5,041 $ 266 $ 152,378 Accumulated amortization Balance at January 1, 2023 $ 142,562 $ 5,439 $ 260 $ 148,261 Amortization expense 121 21 — 142 Disposals — ( 420 ) — ( 420 ) Effect of foreign exchange differences — ( 16 ) ( 1 ) ( 17 ) Balance at June 30, 2023 $ 142,683 $ 5,024 $ 259 $ 147,966 Carrying amounts At June 30, 2023 $ 4,388 $ 17 $ 7 $ 4,412 At December 31, 2022 3,197 38 5 3,240

Lease Liabilities (Tables)

Lease Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Lease liabilities [abstract]
Summary of Lease Liabilities	The transactions affecting the lease liabilities during the six months ended June 30, 2023 were as follows: Balance at January 1, 2023 $ 1,487 Additions 12 Interest expense 109 Payments ( 406 ) Lease modification and other remeasurements — Effect of foreign exchange differences 5 Balance at June 30, 2023 $ 1,207 Less current portion of lease liabilities ( 679 ) Long-term portion of lease liabilities $ 528

Provisions (Tables)

Provisions (Tables)	6 Months Ended
	Jun. 30, 2023
Restructuring provision [abstract]
Summary of Provisions	The transactions affecting the provisions during the six months ended June 30, 2023 were as follows: Balance at January 1, 2023 $ 6,690 Decrease to provision during the period ( 320 ) Payments ( 3,238 ) Interest expense 60 Effect of changes in the discount rate ( 26 ) Balance at June 30, 2023 $ 3,166 Less current portion of provision ( 3,166 ) Long-term portion of provision $ —

Warrant Liability (Tables)

Warrant Liability (Tables)	6 Months Ended
	Jun. 30, 2023
Warrant Liability [Abstract]
Schedule of Fair Value of Warrants	The fair value of the November 2020 warrants on the various dates discussed above was calculated using a Black-Scholes option pricing model in a Monte Carlo simulation in order to evaluate the downward adjustment mechanism to the exercise price. The assumptions used at the different valuation dates are provided in the table below: June 30, December 31, 2023 2022 Underlying common share fair value (in USD) $ 6.28 $ 3.25 Remaining life until expiry 2.3 2.8 Volatility 71.0 % 51.0 % Risk-free interest rate 4.75 % 4.26 % Expected dividend rate — — Fair value of a warrant calculated using a $ 0.19 $ — Fair value of exercise price adjustment mechanism $ 0.53 $ 0.12 Illiquidity discount 26.0 % 20.0 % Fair value of a warrant (in USD) $ 0.53 $ 0.10 Fair value of a warrant (in CAD) $ 0.70 $ 0.13

Share Capital and Other Equit_2

Share Capital and Other Equity Instruments (Tables)	6 Months Ended
	Jun. 30, 2023
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Schedule of Changes in Issued and Outstanding Common Share or RSU or Warrants	At June 30, 2023 and 2022, the number of common shares outstanding were as follows: June 30, 2023 June 30, 2022 Number Amount Number Amount Balance - beginning of period 3,104,222 $ 979,849 3,104,222 $ 979,849 Shares issued for milestone achievement (note 4) 145,312 1,313 — — Balance - end of period 3,249,534 $ 981,162 3,104,222 $ 979,849
Schedule of Changes in Number of Stock Options Outstanding and Weighted Average Exercise Price	For stock options having a CAD exercise price, the changes in the number of stock options outstanding during the six months ended June 30, 2023 and 2022 were as follows: June 30, 2023 June 30, 2022 Weighted Weighted average average exercise price exercise price Number ($) Number ($) Balance - beginning of period 101,629 $ 214.46 102,805 $ 215.29 Forfeited ( 1,709 ) 146.12 — — Expired — — ( 8 ) 21,225.00 Balance - end of period 99,920 $ 215.63 102,797 $ 213.65 For options having a USD exercise price, the changes in the number of stock options outstanding during the quarters ended June 2023, and 2022 were as follows: June 30, 2023 June 30, 2022 Weighted Weighted average average exercise price exercise price Number (USD) Number (USD) Balance - beginning of period 130,916 $ 21.52 74,900 $ 34.88 Granted 44,600 3.99 60,850 6.70 Forfeited ( 5,166 ) 16.34 ( 4,500 ) 18.08 Balance - end of period 170,350 $ 17.09 131,250 $ 22.39
Summary of Weighted Average Inputs into Model and Resulting Grant Date Fair Values	The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options at the date of grant. The weighted average inputs into the model and the resulting grant date fair values during the quarters ended June 30, 2023 and 2022 were as follows: June 30, June 30, 2023 2022 Expected dividend rate — — Expected volatility of share price 117.2 % 115.8 % Risk-free interest rate 3.54 % 2.85 % Expected life in years 6.8 6.8 Weighted average grant date fair value $ 4.65 $ 7.50
Schedule of Stock Options Issued and Outstanding by Range of Exercise Price	At June 30, 2023, stock options issued and outstanding denominated in CAD and USD by range of exercise price are as follows: Weighted Weighted Weighted Range of exercise remaining average average price for stock option Number contractual life exercise price Number exercise price issued in CAD outstanding (in years) ($) exercisable ($) $ 119.90 -$ 146.35 15,399 6.8 $ 136.57 13,079 $ 136.15 $ 146.36 -$ 211.05 78,973 5.9 152.10 68,197 152.10 $ 211.06 - $ 2,130.00 5,025 5.9 358.66 5,025 358.66 $ 2,130.01 -$ 20,700.00 523 5.0 10,761.57 523 10,761.57 99,920 6.1 $ 215.63 86,824 $ 225.56 Weighted Weighted Weighted Range of exercise remaining average average price for stock option Number contractual life exercise price Number exercise price issued in USD outstanding (in years) (USD) exercisable (USD) $ 3.99 -$ 4.75 54,600 9.7 $ 4.01 — $ — $ 4.76 -$ 7.80 37,850 8.9 5.40 14,370 5.40 $ 7.81 - $ 15.95 16,500 8.7 10.20 5,169 10.20 $ 15.96 -$ 41.80 31,400 8.2 27.56 18,939 31.42 $ 41.81 - $ 108.00 30,000 7.4 48.48 27,164 48.28 170,350 8.7 $ 17.09 65,642 $ 31.03
Schedule of Total Share-Based Payments Expense	The total share-based payments compensation expense has been included in the consolidated statements of operations for the quarters and six months ended June 30, 2023 and 2022 as indicated in the following table: Quarter ended June 30, Six months ended June 30, 2023 2022 2023 2022 Research and development expenses $ 98 $ 256 $ 231 $ 523 Administration expenses 145 281 299 633 $ 243 $ 537 $ 530 $ 1,156
Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Schedule of Changes in Issued and Outstanding Common Share or RSU or Warrants	The following table presents the number of warrants outstanding with an exercise price in CAD during the six months ended June 30, 2023 and 2022: June 30, 2023 June 30, 2022 Weighted Weighted average average exercise price exercise price Number ($) Number ($) Balance of warrants - beginning of period 400 $ 30,000.00 17,273 $ 843.30 Cancelled (note 8) — — ( 16,873 ) 152.10 Expired ( 400 ) 30,000.00 — — Balance of warrants - end of period — $ — 400 $ 30,000.00 At June 30, 2023, the number of warrants outstanding by exercise price were as follows: June 30, 2023 Weighted average exercise price Number (USD) Balance of warrants - end of period 789,472 $ 55.00
Schedule of Warrants Outstanding, Exercise Price, Expiry Rate and Overall Weighted Average Exercise Price	The warrants outstanding at June 30, 2023, their exercise price in USD, expiry rate and the overall weighted average exercise price in both currencies are as follows: Number Expiry Exercise Warrants outstanding with an exercise price in USD 789,472 November 2025 $ 55.00

Nature of Operations and Goin_2

Nature of Operations and Going Concern - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Disclosure Of Nature Of Operations And Going Concern [Abstract]
Net loss from continuing operations	$ (8,975)	$ (6,348)	$ (16,556)	$ (17,536)
Operating cash flows			18,121	$ 13,823
Accumulated deficit	1,098,874		1,098,874		$ 1,082,301
Working capital	$ 16,400		$ 16,400		$ 31,200

Acquisition of Fairhaven Pharma

Acquisition of Fairhaven Pharmaceuticals Inc - Additional Information (Details) - Fairhaven Pharmaceuticals Inc. - Share Purchase Agreement $ in Thousands	3 Months Ended
	Jun. 30, 2023 CAD ($) shares
Disclosure Of Business Combinations [Line Items]
Date of business acquisition	Jul. 17, 2020
Common Shares
Disclosure Of Business Combinations [Line Items]
Business acquisition, ownership percentage	100%
Shares issued for acquisition | shares	145,312
Aggregate value of additional payment in shares | $	$ 1,312
Number of days in average volume weighted trading price	5 days

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Details) - CAD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Indemnified Adjustment Expense Made In Respect Of Research And Development Tax Credit Claims	$ 98	$ 600

Discontinued Operations - Summa

Discontinued Operations - Summary of Net Loss from Discontinued Operations (Details) - CAD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Revenues		$ 112	$ 157	$ 248	$ 157
Expenses
Research and development expenses		(4,339)	(3,942)	(8,508)	(8,317)
Administration expenses		4,776	4,505	8,335	9,205
Total income (loss) from discontinued operations		(166)	123	(17)	147
Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Revenues		0	8	0	15
Expenses
Research and development expenses	[1]	(14)	(389)	(345)	(1,201)
Administration expenses		80	142	261	336
Gain on foreign exchange		0	(12)	0	(12)
Finance costs		2	144	3	145
Total income (loss) from discontinued operations		$ (68)	$ 123	$ 81	$ 747
[1] Expense (income) recognized in regards to an agreement with a CDMO which in the comparative period is accounted for in part as a lease (note 5) and an onerous contract (note 6). These expenses (income) are due to changes to the discounted value caused by changes in inflation and discount rates.

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Cash Flows from Discontinued Operations and the Gain on Sale of Discontinued Operations (Details) - CAD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Net effect of currency exchange rate on cash	$ 18	$ 567
Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Cash flows used in operating activities	(264)	(323)
Cash flows utilized during the period	$ (264)	$ (323)

Accounts Receivable and Others

Accounts Receivable and Others - Summary of Trade and Other Receivables (Details) - CAD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Trade and other receivables [abstract]
Trade and other receivables	$ 788	$ 1,177

Other Long-term Assets - Summar

Other Long-term Assets - Summary of Other Long-Term Assets (Details) - CAD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Other Non Current Assets [Abstract]
Other non-current assets	$ 357	$ 243

Capital Assets - Summary of Cap

Capital Assets - Summary of Capital Assets (Details) $ in Thousands	Jun. 30, 2023 CAD ($)
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	$ 4,344
Ending balance	$ 327

Right-of-use Assets - Summary o

Right-of-use Assets - Summary of Quantitative Information About Right-Of-Use Assets (Details) - CAD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Net book value	$ 1,146
Depreciation expense	(263)	$ (252)
Net book value	$ 895

Right-of-use Assets - Additiona

Right-of-use Assets - Additional Information (Details) - CAD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of quantitative information about right-of-use assets [abstract]
Depreciation, right-of-use assets	$ 263	$ 252

Intangible Assets - Summary of

Intangible Assets - Summary of Intangible Assets (Details) - CAD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Intangible Assets [Line Items]
Beginning balance	$ 3,240
Amortization expense	(142)	$ (141)
Ending balance	4,412
Cost
Disclosure Of Intangible Assets [Line Items]
Beginning balance	151,501
Additions	1,312
Disposals	(420)
Effect of foreign exchange differences	(15)
Ending balance	152,378
Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning balance	(148,261)
Amortization expense	142
Disposals	420
Effect of foreign exchange differences	(17)
Ending balance	(147,966)
Licenses and Other Rights
Disclosure Of Intangible Assets [Line Items]
Beginning balance	3,197
Ending balance	4,388
Licenses and Other Rights | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning balance	145,759
Additions	1,312
Ending balance	147,071
Licenses and Other Rights | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning balance	(142,562)
Amortization expense	121
Ending balance	(142,683)
Patents
Disclosure Of Intangible Assets [Line Items]
Beginning balance	38
Ending balance	17
Patents | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning balance	5,477
Disposals	(420)
Effect of foreign exchange differences	(16)
Ending balance	5,041
Patents | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning balance	(5,439)
Amortization expense	21
Disposals	420
Effect of foreign exchange differences	(16)
Ending balance	(5,024)
Software
Disclosure Of Intangible Assets [Line Items]
Beginning balance	5
Ending balance	7
Software | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning balance	265
Effect of foreign exchange differences	1
Ending balance	266
Software | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning balance	(260)
Effect of foreign exchange differences	(1)
Ending balance	$ (259)

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - Share Purchase Agreement - Fairhaven Pharmaceuticals Inc. $ in Thousands	3 Months Ended
	Jun. 30, 2023 CAD ($) shares
Disclosure Of Intangible Assets [Line Items]
Date of business acquisition	Jul. 17, 2020
Common Shares
Disclosure Of Intangible Assets [Line Items]
Aggregate value of additional payment in shares | $	$ 1,312
Shares issued for acquisition | shares	145,312
Business acquisition, ownership percentage	100%
Number of days in average volume weighted trading price	5 days

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Details) - CAD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Trade and other current payables [abstract]
Trade and other current payables	$ 5,394	$ 5,968

Lease Liabilities - Summary of

Lease Liabilities - Summary of Lease Liabilities (Details) - CAD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Less current portion of lease liabilities	$ (679)	$ (735)
Long-term portion of lease liabilities	528	$ 752
Lease Liabilities
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Balance at January 1, 2023	1,487
Additions	12
Interest expense	109
Payments	(406)
Lease modification and other remeasurements	0
Effect of foreign exchange differences	5
Balance at June 30, 2023	1,207
Less current portion of lease liabilities	(679)
Long-term portion of lease liabilities	$ 528

Provisions - Summary of Provisi

Provisions - Summary of Provisions (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 CAD ($)
Restructuring provision [abstract]
Begining Balance	$ 6,690
Decrease to provision during the period	(320)
Payments	(3,238)
Interest expense	60
Effect of changes in the discount rate	(26)
Ending Balance	3,166
Less current portion of provision	(3,166)
Long-term portion of provisions	$ 0

Warrant Liability - Additional

Warrant Liability - Additional Information (Details) $ in Thousands			3 Months Ended		6 Months Ended
	Nov. 25, 2020 shares	Nov. 03, 2020 $ / shares	Jun. 30, 2023 CAD ($)	Jun. 30, 2022 CAD ($)	Jun. 30, 2023 CAD ($) shares	Jun. 30, 2022 CAD ($)	Dec. 31, 2022 CAD ($)
Disclosure Of Detailed Information About Warrant Liability [Line Items]
Number of warrants issued | shares	789,472				789,472
Warrants expiration date	November 3, 2025
Warrants exercise price per share | $ / shares		$ 55
Warrant description					Each warrant can be exercised to acquire one common share at an exercise price initially set at USD 55.0 and that can be reduced if equity financings are completed at a lower price before its expiry.
Fair value of warrant liability			$ 556		$ 556		$ 106
Change in fair value of warrant liability			(212)	$ 1,064	(450)	$ 1,307
S A L P
Disclosure Of Detailed Information About Warrant Liability [Line Items]
Fair value of warrant liability			$ 278		$ 278		$ 53

Warrant Liability - Schedule of

Warrant Liability - Schedule of Fair Value of Warrants on Various Dates Calculated Using a Black-Scholes Option Pricing Model with Assumptions (Details)	6 Months Ended			12 Months Ended
	Jun. 30, 2023 $ / shares	Jun. 30, 2023 $ / shares	Jun. 30, 2022	Dec. 31, 2022 $ / shares	Dec. 31, 2022 $ / shares
Disclosure Of Detailed Information About Stock Option Assumption [Line Items]
Expected dividend rate	0%	0%	0%
Black Scholes Option Pricing Model
Disclosure Of Detailed Information About Stock Option Assumption [Line Items]
Underlying common share fair value (in USD)	$ 6.28			$ 3.25
Remaining life until expiry	0.023	0.023		0.028	0.028
Volatility	71%	71%		51%	51%
Risk-free interest rate	4.75%	4.75%		4.26%	4.26%
Fair value of a warrant calculated using a Black-Sholes pricing model (in USD)	$ 0.19			$ 0
Fair value of exercise price adjustment mechanism (in USD)	$ 0.53			$ 0.12
Illiquidity discount	26%	26%		20%	20%
Fair value of a warrant | (per share)	$ 0.53	$ 0.7		$ 0.1	$ 0.13

Long-term Debt - Additional Inf

Long-term Debt - Additional Information (Details) - CAD ($) $ / shares in Units, $ in Thousands		6 Months Ended
	Feb. 15, 2022	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings repurchase principal amount	$ 39,123
Borrowings repurchase interest amount	484
Repayment of loans	39,123	$ 0	$ 39,123
Loss on extinguishment of liabilities	292
Legal fees incurred in settlement of debt	40
Gain on Extinguishment of Royalty Payment Obligations	$ 120
Warrant Transaction Member
Disclosure Of Detailed Information About Borrowings [Line Items]
Number of warrants cancelled	16,873
Range of exercise price	$ 152.1	$ 0	$ 152.1
Warrants Held by SALP [Member]
Disclosure Of Detailed Information About Borrowings [Line Items]
Number of warrants cancelled	16,873
Range of exercise price	$ 152.1

Share Capital and Other Equit_3

Share Capital and Other Equity Instruments - Share Capital - Additional Information (Details)	6 Months Ended
	Jun. 30, 2023
Common Shares
Disclosure Of Classes Of Share Capital [Line Items]
Share capital description	unlimited number authorized, participating, carrying one vote per share, entitled to dividends.
Preferred Shares
Disclosure Of Classes Of Share Capital [Line Items]
Share capital description	unlimited number authorized, issuable in one or more series.
Series A Preferred Shares
Disclosure Of Classes Of Share Capital [Line Items]
Share capital description	unlimited number authorized, no par value, non-voting, ranking in priority to the common shares, entitled to the same dividends as the common shares, non-transferable, redeemable at the redemption amount offered for the common shares upon a change in control event.

Share Capital and Other Equit_4

Share Capital and Other Equity Instruments - Schedule of Changes in Issued and Outstanding Common Shares (Details) - CAD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of classes of share capital [abstract]
Balance - beginning of year, Number	3,104,222	3,104,222
Shares issued for milestone achievement (note 4), Number	145,312	0
Balance - end of year, Number	3,249,534	3,104,222
Balance - beginning of year	$ 979,849	$ 979,849
Shares issued for milestone achievement (note 4)	1,313	0
Balance - end of year	$ 981,162	$ 979,849

Share Capital and Other Equit_5

Share Capital and Other Equity Instruments - Contributed Surplus (Share-Based Payments) - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Mar. 31, 2023 shares Plan $ / shares	Mar. 31, 2022 shares Plan $ / shares	Jun. 30, 2023 CAD ($)	Jun. 30, 2022 CAD ($)	Jun. 30, 2023 CAD ($)	Jun. 30, 2022 CAD ($)
Disclosure Of Classes Of Share Capital [Line Items]
Number of stock option plan | Plan	2	2
Share-based payment compensation expense | $			$ 243	$ 537	$ 530	$ 1,156
Executives
Disclosure Of Classes Of Share Capital [Line Items]
Number of stock options granted | shares	41,500	11,500
Exercise price of options granted | $ / shares	$ 3.99	$ 10.2
Vesting period	4 years	4 years
Employees
Disclosure Of Classes Of Share Capital [Line Items]
Number of stock options granted | shares	3,100
Exercise price of options granted | $ / shares	$ 3.99
Board of Directors
Disclosure Of Classes Of Share Capital [Line Items]
Number of stock options granted | shares		5,000
Exercise price of options granted | $ / shares		$ 10.2
Stock Options
Disclosure Of Classes Of Share Capital [Line Items]
Share-based payment compensation expense | $			$ 243	$ 537	$ 530	$ 1,156

Share Capital and Other Equit_6

Share Capital and Other Equity Instruments - Schedule of Changes in Number of Stock Options Outstanding and Weighted Average Exercise Price (Details)	6 Months Ended
	Jun. 30, 2023 shares $ / shares	Jun. 30, 2022 shares $ / shares
Disclosure Of Classes Of Share Capital [Line Items]
Number of Share Options, Beginning Balance | shares	101,629	102,805
Number of Share Options, Forfeited | shares	(1,709)	0
Number of Share Options, Expired | shares	0	(8)
Number of share Options, Ending Balance | shares	99,920	102,797
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 214.46	$ 215.29
Weighted Average Exercise Price, Forfeited | $ / shares	146.12	0
Weighted Average Exercise Price, Expired | $ / shares	0	21,225
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 215.63	$ 213.65
US$
Disclosure Of Classes Of Share Capital [Line Items]
Number of Share Options, Beginning Balance | shares	130,916	74,900
Number of Share Options, Granted | shares	44,600	60,850
Number of Share Options, Forfeited | shares	(5,166)	(4,500)
Number of share Options, Ending Balance | shares	170,350	131,250
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 21.52	$ 34.88
Weighted Average Exercise Price, Granted | $ / shares	3.99	6.7
Weighted Average Exercise Price, Forfeited | $ / shares	16.34	18.08
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 17.09	$ 22.39

Share Capital and Other Equit_7

Share Capital and Other Equity Instruments - Summary of Weighted Average Inputs into Model and Resulting Grant Date Fair Values (Details)	6 Months Ended
	Jun. 30, 2023 yr $ / shares	Jun. 30, 2022 yr $ / shares
Disclosure of classes of share capital [abstract]
Expected dividend rate	0%	0%
Expected volatility of share price	117.20%	115.80%
Risk-free interest rate	3.54%	2.85%
Expected life in years | yr	6.8	6.8
Weighted average grant date incremental fair value | $ / shares	$ 4.65	$ 7.5

Share Capital and Other Equit_8

Share Capital and Other Equity Instruments - Schedule of Stock Options Issued and Outstanding by Range of Exercise Price (Details)	6 Months Ended
	Jun. 30, 2023 shares $ / shares	Dec. 31, 2022 shares $ / shares	Jun. 30, 2022 shares $ / shares	Dec. 31, 2021 shares $ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	99,920	101,629	102,797	102,805
Weighted average remaining contractual life (in years)	6 years 1 month 6 days
Options outstanding, weighted average exercise price | $ / shares	$ 215.63	$ 214.46	$ 213.65	$ 215.29
Number exercisable, options | shares	86,824
Options exercisable, weighted average exercise price | $ / shares	$ 225.56
US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	170,350	130,916	131,250	74,900
Weighted average remaining contractual life (in years)	8 years 8 months 12 days
Options outstanding, weighted average exercise price | $ / shares	$ 17.09	$ 21.52	$ 22.39	$ 34.88
Number exercisable, options | shares	65,642
Options exercisable, weighted average exercise price | $ / shares	$ 31.03
$119.90-$146.35
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	15,399
Weighted average remaining contractual life (in years)	6 years 9 months 18 days
Options outstanding, weighted average exercise price | $ / shares	$ 136.57
Number exercisable, options | shares	13,079
Options exercisable, weighted average exercise price | $ / shares	$ 136.15
$146.36-$211.05
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	78,973
Weighted average remaining contractual life (in years)	5 years 10 months 24 days
Options outstanding, weighted average exercise price | $ / shares	$ 152.1
Number exercisable, options | shares	68,197
Options exercisable, weighted average exercise price | $ / shares	$ 152.1
$211.06 - $2,130.00
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	5,025
Weighted average remaining contractual life (in years)	5 years 10 months 24 days
Options outstanding, weighted average exercise price | $ / shares	$ 358.66
Number exercisable, options | shares	5,025
Options exercisable, weighted average exercise price | $ / shares	$ 358.66
$2,130.01-$20,700.00
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	523
Weighted average remaining contractual life (in years)	5 years
Options outstanding, weighted average exercise price | $ / shares	$ 10,761.57
Number exercisable, options | shares	523
Options exercisable, weighted average exercise price | $ / shares	$ 10,761.57
$3.99-$4.75 | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	54,600
Weighted average remaining contractual life (in years)	9 years 8 months 12 days
Options outstanding, weighted average exercise price | $ / shares	$ 4.01
Number exercisable, options | shares	0
Options exercisable, weighted average exercise price | $ / shares	$ 0
$4.76-$7.80 | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	37,850
Weighted average remaining contractual life (in years)	8 years 10 months 24 days
Options outstanding, weighted average exercise price | $ / shares	$ 5.4
Number exercisable, options | shares	14,370
Options exercisable, weighted average exercise price | $ / shares	$ 5.4
$7.81 - $15.95 | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	16,500
Weighted average remaining contractual life (in years)	8 years 8 months 12 days
Options outstanding, weighted average exercise price | $ / shares	$ 10.2
Number exercisable, options | shares	5,169
Options exercisable, weighted average exercise price | $ / shares	$ 10.2
$15.96-$41.80 | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	31,400
Weighted average remaining contractual life (in years)	8 years 2 months 12 days
Options outstanding, weighted average exercise price | $ / shares	$ 27.56
Number exercisable, options | shares	18,939
Options exercisable, weighted average exercise price | $ / shares	$ 31.42
$41.81 - $108.00 | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	30,000
Weighted average remaining contractual life (in years)	7 years 4 months 24 days
Options outstanding, weighted average exercise price | $ / shares	$ 48.48
Number exercisable, options | shares	27,164
Options exercisable, weighted average exercise price | $ / shares	$ 48.28

Share Capital and Other Equit_9

Share Capital and Other Equity Instruments - Schedule of Stock Options Issued and Outstanding by Range of Exercise Price (Parenthetical) (Details)	Jun. 30, 2023 $ / shares
$119.90-$146.35 | Bottom of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	$ 119.9
$119.90-$146.35 | Top of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	146.35
$146.36-$211.05 | Bottom of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	146.36
$146.36-$211.05 | Top of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	211.05
$211.06 - $2,130.00 | Bottom of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	211.06
$211.06 - $2,130.00 | Top of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	2,130
$2,130.01-$20,700.00 | Bottom of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	2,130.01
$2,130.01-$20,700.00 | Top of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	20,700
$3.99-$4.75 | Bottom of Range | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	3.99
$3.99-$4.75 | Top of Range | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	4.75
$4.76-$7.80 | Bottom of Range | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	4.76
$4.76-$7.80 | Top of Range | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	7.8
$7.81 - $15.95 | Bottom of Range | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	7.81
$7.81 - $15.95 | Top of Range | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	15.95
$15.96-$41.80 | Bottom of Range | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	15.96
$15.96-$41.80 | Top of Range | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	41.8
$41.81 - $108.00 | Bottom of Range | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	41.81
$41.81 - $108.00 | Top of Range | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	$ 108

Share Capital and Other Equi_10

Share Capital and Other Equity Instruments - Schedule of Total Share-Based Payments Expense (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based payments expense	$ 243	$ 537	$ 530	$ 1,156
Administration Expenses
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based payments expense	145	281	299	633
Research and Development Expenses
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based payments expense	$ 98	$ 256	$ 231	$ 523

Share Capital and Other Equi_11

Share Capital and Other Equity Instruments - Summary of Changes in Number of Warrants Outstanding and Weighted Average Exercise Price (Details) - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Feb. 15, 2022
Warrant Transaction [Member]
Disclosure of classes of share capital [line items]
Number of warrants, beginning of year	400	17,273
Number of warrants, ending of year	0	400
Weighted average exercise price, beginning of year	$ 30,000	$ 843.3
Number of Warrant Cancelled	0	(16,873)
Number of Warrant Expired	(400)	0
Exercise price of outstanding share options	$ 0	$ 152.1	$ 152.1
Weighted average exercise price, Expired	30,000	0
Weighted average exercise price, end of year	$ 0	$ 30,000
US$
Disclosure of classes of share capital [line items]
Number of warrants, ending of year	789,472
Weighted average exercise price, end of year	$ 55

Share Capital and Other Equi_12

Share Capital and Other Equity Instruments - Warrants - Additional Information (Details) - $ / shares		6 Months Ended
	Nov. 25, 2020	Jun. 30, 2023	Jun. 30, 2022	Feb. 15, 2022
Disclosure Of Classes Of Share Capital [Line Items]
Number of warrants issued	789,472	789,472
Warrant Transaction [Member]
Disclosure Of Classes Of Share Capital [Line Items]
Range of exercise price		$ 0	$ 152.1	$ 152.1
Number of warrants cancelled				16,873

Share Capital and Other Equi_13

Share Capital and Other Equity Instruments - Schedule of Warrants Outstanding, Exercise Price, Expiry Rate and Overall Weighted Average Exercise Price (Details) - Warrant Expires on November 2025	6 Months Ended
	Jun. 30, 2023 Warrant $ / shares
Disclosure Of Classes Of Share Capital [Line Items]
Number or warrants outstanding | Warrant	789,472
Expiry date	Nov. 30, 2025
Exercise price (USD) | $ / shares	$ 55

Capital Management - Summary of

Capital Management - Summary of Capital Management (Details) - CAD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Disclosure Of Capital Management [Abstract]
Warrant liability	$ 556	$ 106
Total equity	$ 21,475	$ 36,208	$ 17,652	$ 33,881

Supplemental Information - Addi

Supplemental Information - Additional Information (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 CAD ($)
Lease Liabilities
Supplemental Information Of Statements Of Operations [Line Items]
Interest expense on lease liabilities	$ 109

Supplemental Information - Summ

Supplemental Information - Summary of Consolidated Statements of Operations (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Supplemental Information Of Statements Of Operations [Line Items]
Total income (loss) from discontinued operations	$ (166)	$ 123	$ (17)	$ 147
Research and development expense	4,339	3,942	8,508	8,317
Administration expenses	$ 4,776	$ 4,505	8,335	9,205
Share-based payments expense			$ 530	$ 1,156

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Recovery in Consolidated Statement of Operations (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Loss from continuing operations, net of taxes of $nil	$ 0	$ 0	$ 0	$ 0

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Related Party Transactions [Line Items]
Cash paid to related party			$ 188
Former Chief Executive Officer [Member]
Related Party Transactions [Line Items]
Owing amount under tax equalization program	$ 197		197		$ 197
S A L P
Related Party Transactions [Line Items]
Legal expenses	$ 53	$ 46	$ 117	$ 205

Financial Instruments and Finan

Financial Instruments and Financial Risk Management - Schedule of Contractual Maturities of Financial Liabilities (Details) - CAD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Disclosure Of Maturity Analysis For Nonderivative Financial Liabilities [Line Items]
Trade and other current payables	$ 5,394	$ 5,968

Financial Instruments and Fin_2

Financial Instruments and Financial Risk Management - Schedule of Net Exposure to Currency Risk through Financial Assets and Financial Liabilities (Details) - CAD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022
Disclosure Of Risk Management Strategy Related To Hedge Accounting [Line Items]
Cash	$ 19,311		$ 42,914
Accounts payable and accrued liabilities	$ (5,394)	$ (5,968)

Subsequent Event - Additional I

Subsequent Event - Additional Information (Details)	Jul. 11, 2023 $ / shares	Apr. 04, 2023 $ / shares
Disclosure of non-adjusting events after reporting period [line items]
Common stock, Cash per share	$ 8.5
Share premium, Percentage	135%
Common stock, Value per share		$ 1